CXCR4 and breast carcinoma: The CXCR4–CXCL12 axis has been extensively studied in breast-to-bone metastasis, where the pharmacological blockade of this pathway using the CXCR4 antagonist AMD3100 (Plerixafor) has been shown to reduce the migration of breast cancer stem cells to bone [27].